Esperion Therapeutics Inc (ESPR) was Downgraded by WallachBeth to ” Hold” and the brokerage firm has set the Price Target at $35. Earlier the firm had a rating of “Buy ” on the company shares. WallachBeth advised their investors in a research report released on Jul 5, 2016.
Many Wall Street Analysts have commented on Esperion Therapeutics Inc. Shares were Reiterated by Needham on Jun 30, 2016 to “Buy” and Lowered the Price Target to $ 25 from a previous price target of $77 .Shares were Downgraded by RBC Capital Mkts on Jun 29, 2016 to ” Sector Perform” and Lowered the Price Target to $ 15 from a previous price target of $30 .Esperion Therapeutics Inc was Downgraded by JP Morgan to ” Neutral” on Jun 29, 2016.
On the company’s financial health, Esperion Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $-0.64.During the same quarter in the previous year, the company posted $-0.49 EPS.
Esperion Therapeutics Inc opened for trading at $10.15 and hit $10.5 on the upside on Friday, eventually ending the session at $10.35, with a gain of 4.76% or 0.47 points. The heightened volatility saw the trading volume jump to 15,66,097 shares. Company has a market cap of $233 M.
In a different news, on May 5, 2016, Timothy M Mayleben (CEO) purchased 7,000 shares at $14.85 per share price. According to the SEC, on Mar 2, 2016, Gilbert S Omenn (director) purchased 5,000 shares at $15.28 per share price. On Apr 27, 2015, Dov A Md Goldstein (director) sold 217,469 shares at $107.73 per share price, according to the Form-4 filing with the securities and exchange commission.
Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.